The reason for the substantial increase in CS1 following bortezomib and melphalan treatment remains unknown, but a prior study observed a ~1.5-fold increase in CS1 expression post-melphalan treatment in myeloma cells [54]. This evidence concerns the gene SLAMF7 and plasma cell myeloma.